Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life

Research output: Contribution to journalArticlepeer-review

Standard

Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer : effects on survival and quality of life. / Cullen, M H; Billingham, L J; Woodroffe, C M; Chetiyawardana, A D; Gower, N H; Joshi, R; Ferry, D R; Rudd, R M; Spiro, S G; Cook, J E; Trask, C; Bessell, E; Connolly, C K; Tobias, J; Souhami, R L.

In: Journal of Clinical Oncology , Vol. 17, No. 10, 10.1999, p. 3188-94.

Research output: Contribution to journalArticlepeer-review

Harvard

Cullen, MH, Billingham, LJ, Woodroffe, CM, Chetiyawardana, AD, Gower, NH, Joshi, R, Ferry, DR, Rudd, RM, Spiro, SG, Cook, JE, Trask, C, Bessell, E, Connolly, CK, Tobias, J & Souhami, RL 1999, 'Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life', Journal of Clinical Oncology , vol. 17, no. 10, pp. 3188-94.

APA

Cullen, M. H., Billingham, L. J., Woodroffe, C. M., Chetiyawardana, A. D., Gower, N. H., Joshi, R., Ferry, D. R., Rudd, R. M., Spiro, S. G., Cook, J. E., Trask, C., Bessell, E., Connolly, C. K., Tobias, J., & Souhami, R. L. (1999). Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. Journal of Clinical Oncology , 17(10), 3188-94.

Vancouver

Author

Cullen, M H ; Billingham, L J ; Woodroffe, C M ; Chetiyawardana, A D ; Gower, N H ; Joshi, R ; Ferry, D R ; Rudd, R M ; Spiro, S G ; Cook, J E ; Trask, C ; Bessell, E ; Connolly, C K ; Tobias, J ; Souhami, R L. / Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer : effects on survival and quality of life. In: Journal of Clinical Oncology . 1999 ; Vol. 17, No. 10. pp. 3188-94.

Bibtex

@article{608c6297ef8b4d8681536d00f0d55b6f,
title = "Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life",
abstract = "Chemotherapy for non-small-cell lung cancer (NSCLC) remains controversial. We describe the two largest reported, randomized, parallel trials designed to determine whether the addition of chemotherapy influences duration and quality of life in localized, unresectable (mitomycin, ifosfamide, cisplatin [MIC]1 trial) and extensive (MIC2 trial) disease.",
keywords = "Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Cisplatin, Female, Humans, Ifosfamide, Lung Neoplasms, Male, Middle Aged, Mitomycin, Prognosis, Quality of Life, Survival Analysis",
author = "Cullen, {M H} and Billingham, {L J} and Woodroffe, {C M} and Chetiyawardana, {A D} and Gower, {N H} and R Joshi and Ferry, {D R} and Rudd, {R M} and Spiro, {S G} and Cook, {J E} and C Trask and E Bessell and Connolly, {C K} and J Tobias and Souhami, {R L}",
year = "1999",
month = oct,
language = "English",
volume = "17",
pages = "3188--94",
journal = "Journal of Clinical Oncology ",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "10",

}

RIS

TY - JOUR

T1 - Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer

T2 - effects on survival and quality of life

AU - Cullen, M H

AU - Billingham, L J

AU - Woodroffe, C M

AU - Chetiyawardana, A D

AU - Gower, N H

AU - Joshi, R

AU - Ferry, D R

AU - Rudd, R M

AU - Spiro, S G

AU - Cook, J E

AU - Trask, C

AU - Bessell, E

AU - Connolly, C K

AU - Tobias, J

AU - Souhami, R L

PY - 1999/10

Y1 - 1999/10

N2 - Chemotherapy for non-small-cell lung cancer (NSCLC) remains controversial. We describe the two largest reported, randomized, parallel trials designed to determine whether the addition of chemotherapy influences duration and quality of life in localized, unresectable (mitomycin, ifosfamide, cisplatin [MIC]1 trial) and extensive (MIC2 trial) disease.

AB - Chemotherapy for non-small-cell lung cancer (NSCLC) remains controversial. We describe the two largest reported, randomized, parallel trials designed to determine whether the addition of chemotherapy influences duration and quality of life in localized, unresectable (mitomycin, ifosfamide, cisplatin [MIC]1 trial) and extensive (MIC2 trial) disease.

KW - Adult

KW - Aged

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Carcinoma, Non-Small-Cell Lung

KW - Cisplatin

KW - Female

KW - Humans

KW - Ifosfamide

KW - Lung Neoplasms

KW - Male

KW - Middle Aged

KW - Mitomycin

KW - Prognosis

KW - Quality of Life

KW - Survival Analysis

M3 - Article

C2 - 10506617

VL - 17

SP - 3188

EP - 3194

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 10

ER -